<table border="0" cellpadding="0" cellspacing="0" width="630" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4 Established and Potential Drug Interactions: Use With Caution, Alteration in Dose or Regimen May Be Needed Due to Drug Interaction Established Drug Interactions: See <linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>, Table 5 for Magnitude of Interaction. 
			</caption>
<thead>
<tr>
<th align="center" stylecode="Lrule Rrule Toprule">Drug Name </th>
<th align="center" stylecode="Lrule Rrule Toprule">Effect on Concentration of<br/>Nevirapine or Concomitant<br/>Drug </th>
<th align="center" stylecode="Lrule Rrule Toprule">Clinical Comment </th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Atazanavir/Ritonavir<br/>
</td>
<td stylecode="Rrule" valign="top">↓ Atazanavir<br/> <br/>↑ Nevirapine<br/>
</td>
<td stylecode="Rrule" valign="top">Do not co-administer nevirapine with atazanavir<br/>because nevirapine substantially decreases<br/>atazanavir exposure.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top"> <br/>Clarithromycin <br/>
</td>
<td stylecode="Rrule" valign="top"> <br/>↓ Clarithromycin <br/> <br/>↑ 14-OH clarithromycin <br/>
</td>
<td stylecode="Rrule" valign="top">Clarithromycin exposure was significantly<br/>decreased by nevirapine; however, 14-OH<br/>metabolite concentrations were increased.<br/>Because clarithromycin active metabolite has<br/>reduced activity against <content stylecode="italics">Mycobacterium avium-</content>
<br/>
<content stylecode="italics">intracellulare complex</content>, overall activity against <br/>this pathogen may be altered. Alternatives to<br/>clarithromycin, such as azithromycin, should<br/>be considered.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Efavirenz <br/>
</td>
<td stylecode="Rrule" valign="top">↓ Efavirenz <br/>
</td>
<td stylecode="Rrule" valign="top">There has been no determination of appropriate<br/>doses for the safe and effective use of this<br/>combination <content stylecode="italics">[see <linkhtml href="#Section_5.4"></linkhtml>
</content>
<br/>
<content stylecode="italics">
<linkhtml href="#Section_5.4">Warnings and Precautions  (5.4)</linkhtml>
</content>
<content stylecode="italics">]</content>.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top"> <br/>Ethinyl estradiol and Norethindrone <br/>
</td>
<td stylecode="Rrule" valign="top"> <br/>↓ Ethinyl estradiol <br/> <br/>↓ Norethindrone <br/>
</td>
<td stylecode="Rrule" valign="top">Oral contraceptives and other hormonal<br/>methods of birth control should not be used as <br/>the sole method of contraception in women<br/>taking nevirapine, since nevirapine may lower<br/>the plasma levels of these medications. An <br/>alternative or additional method of <br/>contraception is recommended. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top"> <br/>Fluconazole <br/>
</td>
<td stylecode="Rrule" valign="top"> <br/>↑ Nevirapine <br/>
</td>
<td stylecode="Rrule" valign="top">Because of the risk of increased exposure to<br/>nevirapine, caution should be used in<br/>concomitant administration, and patients<br/>should be monitored closely for nevirapine<br/>-associated adverse events.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Fosamprenavir<br/>
</td>
<td stylecode="Rrule" valign="top">↓Amprenavir<br/> <br/> <br/>↑Nevirapine<br/>
</td>
<td stylecode="Rrule" valign="top">Co-administration of nevirapine and<br/>fosamprenavir without ritonavir is not<br/>recommended.<br/> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Fosamprenavir/Ritonavir<br/>
</td>
<td stylecode="Rrule" valign="top">↓Amprenavir<br/> <br/> <br/>↑Nevirapine<br/>
</td>
<td stylecode="Rrule" valign="top">No dosing adjustments are required when<br/>nevirapine is co-administered with 700/100 mg<br/>of fosamprenavir/ritonavir twice daily.<br/> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top"> <br/>Indinavir <br/>
</td>
<td stylecode="Rrule" valign="top"> <br/>↓ Indinavir <br/>
</td>
<td stylecode="Rrule" valign="top">Appropriate doses for this combination are not<br/>established, but an increase in the dosage of <br/>indinavir may be required.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top"> <br/>Ketoconazole <br/>
</td>
<td stylecode="Rrule" valign="top"> <br/>↓ Ketoconazole <br/>
</td>
<td stylecode="Rrule" valign="top">Nevirapine and ketoconazole should not be<br/>administered concomitantly because decreases<br/>in ketoconazole plasma concentrations may<br/>reduce the efficacy of the drug.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top"> <br/>Lopinavir/Ritonavir <br/>
</td>
<td stylecode="Rrule" valign="top"> <br/>↓Lopinavir <br/>
</td>
<td stylecode="Rrule" valign="top">A dose increase of lopinavir/ritonavir tablets to<br/>500/125 mg twice-daily is recommended when<br/>used in combination with nevirapine.<br/> <br/>A dose increase of lopinavir/ritonavir oral<br/>solution to 533/133 mg twice daily with food is<br/>recommended in combination with nevirapine.<br/> <br/>In children 6 months to 12 years of age<br/>receiving lopinavir/ritonavir solution,<br/>consideration should be given to increasing the<br/>dose of lopinavir/ritonavir to 13/3.25 mg/kg for<br/>those 7 to &lt;15 kg; 11/2.75 mg/kg for those 15<br/>to 45 kg; and up to a maximum dose of 533/<br/>133 mg twice daily.<br/> <br/>Refer to the lopinavir/ritonavir package insert<br/>for complete pediatric dosing instructions when<br/>lopinavir/ritonavir tablets are used in<br/>combination with nevirapine.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top"> <br/>Methadone <br/>
</td>
<td stylecode="Rrule" valign="top"> <br/>↓ Methadone<sup></sup>
<br/>
</td>
<td stylecode="Rrule" valign="top">Methadone levels were decreased; increased<br/>dosages may be required to prevent symptoms<br/>of opiate withdrawal. Methadone-maintained<br/>patients beginning nevirapine therapy should be<br/>monitored for evidence of withdrawal and<br/>methadone dose should be adjusted <br/>accordingly.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top"> <br/>Nelfinavir <br/>
</td>
<td stylecode="Rrule" valign="top">↓ Nelfinavir M8 Metabolite ↓ Nelfinavir C<sub>min </sub>
<br/>
</td>
<td stylecode="Rrule" valign="top">The appropriate dose for nelfinavir in<br/>combination with nevirapine, with respect to<br/>safety and efficacy, has not been established. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top"> <br/>Rifabutin<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↑ Rifabutin<br/>
</td>
<td stylecode="Rrule" valign="top">Rifabutin and its metabolite concentrations<br/>were moderately increased. Due to high<br/>intersubject variability, however, some patients<br/>may experience large increases in rifabutin<br/>exposure and may be at higher risk for rifabutin<br/>toxicity. Therefore, caution should be used in<br/>concomitant administration.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top"> <br/>Rifampin <br/>
</td>
<td stylecode="Rrule" valign="top"> <br/>↓ Nevirapine<br/>
</td>
<td stylecode="Rrule" valign="top">Nevirapine and rifampin should not be<br/>administered concomitantly because decreases<br/>in nevirapine plasma concentrations may<br/>reduce the efficacy of the drug. Physicians<br/>needing to treat patients co-infected with<br/>tuberculosis and using a nevirapine-containing <br/>regimen may use rifabutin instead.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top"> <br/>Saquinavir/Ritonavir<br/>
</td>
<td stylecode="Rrule" valign="top">The interaction between<br/>nevirapine and<br/>saquinavir/ritonavir has not<br/>been evaluated<br/>
</td>
<td stylecode="Rrule" valign="top">The appropriate doses of the combination of<br/>nevirapine and saquinavir/ritonavir with<br/>respect to safety and efficacy have not been<br/>established.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">
<content stylecode="italics">Potential </content>Drug Interactions:</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Drug Class</content>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Examples of Drugs</content>
<br/>
</td>
<td stylecode="Rrule" valign="top"> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Antiarrhythmics<br/>
</td>
<td stylecode="Rrule" valign="top">Amiodarone, disopyramide,<br/>lidocaine<br/>
</td>
<td stylecode="Rrule" valign="top">Plasma concentrations may be decreased.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Anticonvulsants<br/>
</td>
<td stylecode="Rrule" valign="top">Carbamazepine, clonazepam,<br/>ethosuximide<br/>
</td>
<td stylecode="Rrule" valign="top">Plasma concentrations may be decreased.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Antifungals<br/>
</td>
<td stylecode="Rrule" valign="top">Itraconazole<br/>
</td>
<td stylecode="Rrule" valign="top">Plasma concentrations of some azole<br/>antifungals may be decreased. Nevirapine and<br/>itraconazole should not be administered<br/>concomitantly due to a potential<sub></sub>decrease in<br/>itraconazole plasma concentrations.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Calcium channel blockers<br/>
</td>
<td stylecode="Rrule" valign="top">Diltiazem, nifedipine,<br/>verapamil<br/>
</td>
<td stylecode="Rrule" valign="top">Plasma concentrations may be decreased.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Cancer chemotherapy<br/>
</td>
<td stylecode="Rrule" valign="top">Cyclophosphamide<br/>
</td>
<td stylecode="Rrule" valign="top">Plasma concentrations may be decreased.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Ergot alkaloids<br/>
</td>
<td stylecode="Rrule" valign="top">Ergotamine<br/>
</td>
<td stylecode="Rrule" valign="top">Plasma concentrations may be decreased.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Immunosuppressants<br/>
</td>
<td stylecode="Rrule" valign="top">Cyclosporin, tacrolimus, sirolimus<br/>
</td>
<td stylecode="Rrule" valign="top">Plasma concentrations may be decreased.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Motility agents<br/>
</td>
<td stylecode="Rrule" valign="top">Cisapride<br/>
</td>
<td stylecode="Rrule" valign="top">Plasma concentrations may be decreased.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Opiate agonists<br/>
</td>
<td stylecode="Rrule" valign="top">Fentanyl<br/>
</td>
<td stylecode="Rrule" valign="top">Plasma concentrations may be decreased.<br/>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule" valign="top">Antithrombotics<br/>
</td>
<td stylecode="Rrule" valign="top">Warfarin<br/>
</td>
<td stylecode="Rrule" valign="top">Plasma concentrations may be increased.<br/>Potential effect on anticoagulation. Monitoring <br/>of anticoagulation levels is recommended.<br/>
</td>
</tr>
</tbody>
</table>